Please provide your email address to receive an email when new articles are posted on . The first presentation given at ACR Convergence 2024 that she spoke about evaluated the association between RA ...
A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk.
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients ...
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response ...
There is good news for patients with rheumatoid arthritis. Research from Aarhus University and Aarhus University Hospital may have opened the door to an entirely new way of reducing inflammation in ...
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting ...
Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...
Dr. Chidiebere D. Akusobi (Medicine): A 44-year-old woman was evaluated in the rheumatology clinic of this hospital because of proximal muscle weakness and myalgia. The patient had been in her usual ...
- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis - Presentations to highlight patient-reported outcomes of RINVOQ ...
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, includin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results